Yellow fever virus: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
− | == |
+ | ==Background== |
− | === |
+ | ===Microbiology=== |
− | * |
+ | *RNA virus and member of the [[Flaviviridae]] family |
− | == |
+ | === Epidemiology === |
+ | * Worldwide, about 200,000 cases and 30,000 deaths annually |
||
⚫ | |||
+ | |||
+ | == Clinical Manifestations == |
||
+ | |||
+ | * Spectrum of illness from asymptomatic to fatal |
||
+ | * Acute illness starts with fever, chills, headache, backache, myalgias, arthralgias, nausea, vomiting, photophobia, mild jaundice, and epigastric pain |
||
+ | * After the acute illness subsides, about 85% of infections are resolved, and 15% progress |
||
+ | * In those who progress, a brief remission of hours to days is followed by return of symptoms with progression to renal failure, hemorrhage, and thrombocytopenia |
||
+ | |||
+ | === Vaccine-Related Disease === |
||
+ | |||
+ | * [[Yellow fever vaccine-associated neurotropic disease]], which includes [[meningoencephalitis]], [[Guillain-Barré syndrome]], and acute bulbar palsy |
||
+ | * [[Yellow fever vaccine-associated viscerotropic disease]], which causes multi-organ failure similar to wildtype virus |
||
+ | |||
+ | {| class="wikitable" |
||
+ | ! |
||
+ | ![[Yellow fever vaccine-associated neurotropic disease|YEL-AND]] |
||
+ | ![[Yellow fever vaccine-associated viscerotropic disease|YEL-AVD]] |
||
+ | |- |
||
+ | |Incubation period |
||
+ | |7 to 21 days |
||
+ | |2 to 5 days |
||
+ | |- |
||
+ | |Rate |
||
+ | |0.8 per 100,000 doses |
||
+ | |1 per 100,000 doses |
||
+ | |- |
||
+ | |Risk factors |
||
+ | |age <6 months |
||
+ | age >60-70 years |
||
+ | |age >60 years |
||
+ | thymus disease |
||
+ | |- |
||
+ | |Prognosis |
||
+ | |full recovery |
||
+ | |65% mortality |
||
+ | |} |
||
+ | |||
+ | == Management == |
||
+ | |||
+ | * Supportive care |
||
+ | |||
+ | ==Prevention== |
||
+ | |||
+ | *A live attenuated vaccine strain is available |
||
+ | *Contraindications |
||
+ | **Allergy to any component of the vaccine |
||
+ | **Infants less than 6 to 9 months of age, due to the high risk of [[Yellow fever vaccine-associated neurotropic disease|neurotropic disease]] following immunization |
||
+ | **People age 60 years and older, due to the high risk of adverse events following immunization |
||
+ | ***Booster doses may stll be given, if indicated |
||
+ | **Pregnancy and breastfeeding |
||
+ | **Thymus disease, including [[thymoma]], [[thymectomy]], and [[myasthenia gravis]], given the high risk of [[Yellow fever vaccine-associated viscerotropic disease|viscerotropic disease]] |
||
+ | **Moderate or severe acute illness |
||
⚫ | |||
[[Category:Flaviviridae]] |
[[Category:Flaviviridae]] |
Revision as of 20:24, 16 September 2020
Background
Microbiology
- RNA virus and member of the Flaviviridae family
Epidemiology
- Worldwide, about 200,000 cases and 30,000 deaths annually
Clinical Manifestations
- Spectrum of illness from asymptomatic to fatal
- Acute illness starts with fever, chills, headache, backache, myalgias, arthralgias, nausea, vomiting, photophobia, mild jaundice, and epigastric pain
- After the acute illness subsides, about 85% of infections are resolved, and 15% progress
- In those who progress, a brief remission of hours to days is followed by return of symptoms with progression to renal failure, hemorrhage, and thrombocytopenia
Vaccine-Related Disease
- Yellow fever vaccine-associated neurotropic disease, which includes meningoencephalitis, Guillain-Barré syndrome, and acute bulbar palsy
- Yellow fever vaccine-associated viscerotropic disease, which causes multi-organ failure similar to wildtype virus
YEL-AND | YEL-AVD | |
---|---|---|
Incubation period | 7 to 21 days | 2 to 5 days |
Rate | 0.8 per 100,000 doses | 1 per 100,000 doses |
Risk factors | age <6 months
age >60-70 years |
age >60 years
thymus disease |
Prognosis | full recovery | 65% mortality |
Management
- Supportive care
Prevention
- A live attenuated vaccine strain is available
- Contraindications
- Allergy to any component of the vaccine
- Infants less than 6 to 9 months of age, due to the high risk of neurotropic disease following immunization
- People age 60 years and older, due to the high risk of adverse events following immunization
- Booster doses may stll be given, if indicated
- Pregnancy and breastfeeding
- Thymus disease, including thymoma, thymectomy, and myasthenia gravis, given the high risk of viscerotropic disease
- Moderate or severe acute illness
- Vaccination can cause YF vaccine-associated neurotropic disease and YF vaccine-associated viscerotropic disease